08 nov: Langsigtet incitamentsprogram
08 nov: Offentliggørelse af det individuelle solvensbehov
08-11-2017 17:01:17

Genmab Announces Financial Results for the First Nine Months of 2017

Relateret indhold
19 feb - 
Mandagens aktier: Defensiv nedtur for C25 trods plusser..
19 feb - 
Aktier/middag: Defensive aktier sørger for samlet nedga..
19 feb - 
Genmab OPTAKT Q4 21/2: 2018-prognosen kommer under lup
Relateret debat
19 feb - 
Er ret enig i dine betragtninger. Ryger aktien 5-10% læ..
19 feb - 
Der er i hvert fald skræmmende ligheder imellem Genmab ..
19 feb - 
Har du kigget på forward p/e?

November 8, 2017; Copenhagen, Denmark;

Interim Report for the First Nine Months Ended September 30, 2017

Highlights

  • USD 871 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 707 million

  • DARZALEX approved for relapsed or refractory multiple myeloma in Japan

  • Announced positive topline results in Phase III ALCYONE study of daratumumab in front line multiple myeloma

  • Seattle Genetics exercised its option to co-develop tisotumab vedotin with Genmab

“This past quarter we continued to focus on progressing our innovative antibody pipeline.  DARZALEX received its first approval in Japan, for the treatment of relapsed or refractory multiple myeloma.  We also reported exciting data from the Phase III ALCYONE study of daratumumab in front line multiple myeloma.  Finally, we were pleased to announce that Seattle Genetics exercised its option to co-develop tisotumab vedotin and we very much look forward to our collaboration to rapidly bring this product into the next stages of clinical evaluation,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance First Nine Months of 2017

  • Revenue was DKK 1,348 million in the first nine months of 2017 compared to DKK 889 million in the first nine months of 2016. The increase of DKK 459 million, or 52%, was mainly driven by higher DARZALEX royalties and milestones.

  • Operating expenses were DKK 707 million in the first nine months of 2017 compared to DKK 544 million in the first nine months of 2016. The increase of DKK 163 million, or 30%, was due to the additional investment in our pipeline of products, including the advancement of tisotumab vedotin,  HexaBody®-DR5/DR5, DuoBody®-CD3xCD20, and other products in our pipeline.

  • Operating income was DKK 641 million in the first nine months of 2017 compared to DKK 345 million in the first nine months of 2016.  The increase of DKK 296 million, or 86%, was driven by higher revenue, which was partly offset by increased operating expenses in 2017.

  • On September 30, 2017, Genmab had a cash position of DKK 5,184 million compared to DKK 3,922 million at December 31, 2016. This represented a net increase of DKK 1,262 million, which was mainly driven by positive working capital adjustments of DKK 575 million related to milestones achieved in the fourth quarter of 2016 that were received in 2017, our operating income of DKK 641 million, and proceeds from the exercise of warrants of DKK 208 million.

Outlook                                                                                          

Genmab is maintaining its 2017 financial guidance published on February 22, 2017 and reiterated on September 27, 2017.

Conference Call

Genmab will hold a conference call in English to discuss the results for the first nine months of 2017 today, Wednesday, November 8, at 6.00 pm CET, 5.00 pm GMT or 12.00 pm EDT. The dial in numbers are:

+1 646 254 3360 (US participants) and ask for the Genmab conference call

+44 20 3427 1910 (international participants) and ask for the Genmab conference call

 

A live and archived webcast of the call and relevant slides will be available at www.genmab.com.

Contact:         

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

The interim report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s annual report, which is available on www.genmab.com and the “Significant Risks and Uncertainties” section in the interim report. Genmab does not undertake any obligation to update or revise forward looking statements in this interim report nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Download the full Interim Report for the first nine months of 2017 on attachment or at www.genmab.com.

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

 

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

 

 

Vedhæftet fil: Q3 2017 Interim Report.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 feb
GEN
Stol på dig selv.men ellers vil jeg da lige nævne at The Note har købt igen og helt sikkert kommer m..
9
19 feb
GEN
Ja aktiemarkedet er blevet et giftigt farvand fyldt med shorte-fonde, manipulerende oplysninger og a..
4
19 feb
GEN
Ja, det er altsammen meget godt. Men det altafgørende er: Hvad siger marc55? Vi ved jo alle sammen g..
4
18 feb
GEN
Så er det jo godt for dig at du har solgt. Jeg er nu meget tryk ved Winkel ved roret, og skal ikke s..
3
17 feb
GEN
Ja, jeg kan godt følge TheNote, Winkel har gjort det af helvede til. Det er utroligt ringe det han h..
3
19 feb
GEN
Ja, vi falder - og det er godt nok længe siden, vi har set Jan på banen med sin jubeloptimisme Måske..
2
19 feb
GEN
Problemet med at spille mod Carnegie er at de jo "bare" lige ringer til et par forhandlere og så ved..
2
19 feb
GEN
Lad os nu se hvad der sker idag og imorgen. AXL/DCL kan blive stort. Tisutumab er paa trapperne. DC3..
2
18 feb
GEN
Nu er det jo ikke sådan at firmaet er gået helt istå. Fremadrettet vil indtjeningen stige med 800-10..
2
16 feb
GEN
Onsdag er ikke noget særligt.   Problemet er at overskuddet de næste par år er begrænset. Der bliver..
2

WDH OPTAKT H2 22/2: Oticon Opn-maskinen skal til eftersyn

19-02-2018 15:42:01
Det helt store spørgsmål på de fleste investorers blokke inden årsregnskabet for 2017 fra William Demant Holding er formentlig, om det trådløse topprodukt inden for høreapparater, Oticon Opn, har kunnet fortsætte med at bidrage til stærk vækst og indtjening i andet halvår.Produktet blev lanceret for godt halvandet år siden og er derfor relativt langt henne i den normale livscyklus for høreapparate..

GN vil have Leo Pharma-topchef ind i bestyrelsen

19-02-2018 14:30:12
Der er lagt op til en enkelt udskiftning i bestyrelsen hos GN Group, når det danske selskab afholder ordinær generalforsamling i hovedkvarteret i Ballerup den 13. marts.Carsten Krogsgaard Thomsen, der er finansdirektør hos NNIT og i øvrigt bror til Mads Krogsgaard Thomsen, der er forskningsdirektør hos Novo Nordisk, har meddelt bestyrelsen, at han ikke ønsker at genopstille.I stedet foreslår GN Gr..

Aktier/middag: Defensive aktier sørger for samlet nedgang til C25

19-02-2018 11:36:39
Mens Mærsk-aktierne stiger forud for tirsdagens kapitalmarkedsdag, så er der fald til flere af de defensive eliteaktier, og det sørger mandag middag for et samlet minus for C25-indekset. Omkring middagstid ligger det danske eliteindeks 0,4 pct. lavere i 1138,49. Holder det dagen hjem, vil det være første gang set over fire handelsdage, at C25-indekset lukker lavere end dagen før.- Der er rimeligt ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Hartmann: Direktør Ulrik Kolding Hartvig død efter cykelulykke
2
Genmab OPTAKT Q4 21/2: 2018-prognosen kommer under lup
3
Aktier/tendens: Mærsk i fokus i ventet positiv åbning
4
Briter har 10 dage til at bruge 1,8 milliarder kroner - citat
5
Novo stævnet sammen med konkurrenter i USA - citat

Relaterede aktiekurser

Genmab A/S 1.047,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. februar 2018 02:51:54
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180219.1 - EUROWEB2 - 2018-02-20 02:51:54 - 2018-02-20 02:51:54 - 1 - Website: OKAY